147,000 Shares in Phathom Pharmaceuticals, Inc. $PHAT Purchased by Hussman Strategic Advisors Inc.

Key Points

• Hussman Strategic Advisors bought 147,000 shares of Phathom (~$2.44M), bringing its stake to about 0.21%, while institutional investors collectively own roughly 99.01% of the company.
• Q1 revenue beat estimates as VOQUEZNA sales grew, but Phathom remains unprofitable with a small EPS miss and issued FY2026 revenue guidance of $320–$345M, a range that leaves some uncertainty versus consensus.
• Shares rose about 7.2% on the news; analysts are mostly bullish with a consensus "Moderate Buy" and a $25 price target amid several recent upgrades.

Hussman Strategic Advisors Inc. bought a new stake in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 147,000 shares of the company's stock, valued at approximately $2,439,000. Hussman Strategic Advisors Inc. owned 0.21% of Phathom Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Jones Financial Companies Lllp increased its position in Phathom Pharmaceuticals by 442.6% during the 3rd quarter. Jones Financial Companies Lllp now owns 2,523 shares of the company's stock valued at $30,000 after purchasing an additional 2,058 shares during the period. Raymond James Financial Inc. purchased a new position in Phathom Pharmaceuticals during the 2nd quarter valued at about $30,000. BNP Paribas Financial Markets increased its position in Phathom Pharmaceuticals by 71.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 5,072 shares of the company's stock valued at $49,000 after purchasing an additional 2,122 shares during the period. Tower Research Capital LLC TRC increased its position in Phathom Pharmaceuticals by 58.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,710 shares of the company's stock valued at $55,000 after purchasing an additional 2,102 shares during the period. Finally, Russell Investments Group Ltd. increased its position in Phathom Pharmaceuticals by 132.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,362 shares of the company's stock valued at $75,000 after purchasing an additional 3,626 shares during the period. Hedge funds and other institutional investors own 99.01% of the company's stock.

Phathom Pharmaceuticals News Summary

Here are the key news stories impacting Phathom Pharmaceuticals this week:

• Positive Sentiment: Q1 revenue beat consensus — Phathom reported $58.3M in revenue (above analyst estimates around $55.9M), showing top-line strength as VOQUEZNA® sales grow. Press Release / Slide Deck
• Positive Sentiment: Commercial visibility at DDW 2026 — Phathom announced it will highlight VOQUEZNA (vonoprazan) at the Digestive Disease Week meeting (May 2–5), which can support ongoing uptake and awareness among GI specialists. DDW Participation
• Neutral Sentiment: Earnings materials and call available — Management provided an earnings presentation and the full call transcript, useful for investors digging into product trends, channel fill, and cost dynamics. (See Seeking Alpha slides/transcript.) Earnings Presentation Earnings Transcript
• Negative Sentiment: Small EPS miss — GAAP/adjusted EPS loss of $0.18 missed consensus by $0.01, continuing an unprofitable profile (loss narrowed year-over-year but still negative). Q1 Results
• Negative Sentiment: FY2026 revenue guidance range implies mixed outlook — management guided revenue of $320M–$345M versus consensus near $331.9M; the range brackets the consensus but the lower bound is below street expectations, leaving some uncertainty on full-year trajectory. (EPS guidance detail was not provided in the entry.)

Phathom Pharmaceuticals Stock Up 7.2%

Shares of Phathom Pharmaceuticals stock opened at $12.01 on Friday. The firm's 50 day moving average price is $11.52 and its 200-day moving average price is $13.43. Phathom Pharmaceuticals, Inc. has a 52-week low of $2.21 and a 52-week high of $18.31. The company has a market cap of $953.95 million, a P/E ratio of -5.67 and a beta of 0.57.

Phathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01. The firm had revenue of $57.58 million during the quarter, compared to analysts' expectations of $57.44 million. As a group, equities research analysts forecast that Phathom Pharmaceuticals, Inc. will post -0.12 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on PHAT. Guggenheim raised their target price on shares of Phathom Pharmaceuticals from $20.00 to $25.00 and gave the company a "buy" rating in a research report on Friday, February 27th. Cantor Fitzgerald reissued an "overweight" rating on shares of Phathom Pharmaceuticals in a research report on Wednesday, January 14th. Stifel Nicolaus set a $28.00 target price on shares of Phathom Pharmaceuticals in a research report on Thursday, February 26th. Barclays raised shares of Phathom Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their target price for the company from $16.00 to $18.00 in a research report on Friday, March 27th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Phathom Pharmaceuticals in a research report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $25.00.

Phathom Pharmaceuticals Profile

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company's core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom's research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company's lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.